Cisplatin
- Generic Name
- Cisplatin
- Brand Names
- Platinol
- Drug Type
- Small Molecule
- Chemical Formula
- Cl2H6N2Pt
- CAS Number
- 15663-27-1
- Unique Ingredient Identifier
- Q20Q21Q62J
- Background
Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
- Indication
For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
- Associated Conditions
- Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
- Associated Therapies
- -
A Study of SGN-B6A in Advanced Solid Tumors
- Conditions
- Squamous Cell Carcinoma of Head and NeckHER2 Negative Breast NeoplasmsCutaneous Squamous Cell CancerExocrine Pancreatic AdenocarcinomaUterine Cervical NeoplasmsCarcinoma, Non-Small Cell LungEsophageal Squamous Cell CarcinomaUrinary Bladder NeoplasmsEsophageal AdenocarcinomaGastroesophageal Junction Adenocarcinoma
- Interventions
- First Posted Date
- 2020-05-15
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 824
- Registration Number
- NCT04389632
- Locations
- 🇨🇳
Taipei Veterans General Hospital, Taipei City, Other, Taiwan
🇺🇸Alaska Oncology and Hematology, Anchorage, Alaska, United States
🇺🇸Highlands Oncology Group, Fayetteville, Arkansas, United States
Safety and Efficacy of Toripalimab in HER2- Metastatic Breast Cancer Patients Treated With Metronomic Vinorelbine
- Conditions
- Metastatic Breast Cancer
- Interventions
- Drug: Vinorelbine 40mgBiological: Toripalimab 240mgDrug: Cyclophosphamide 50 mgBiological: Bevacizumab 5 mg/kgDrug: CisplatinDrug: Capecitabine 500Mg Oral Tablet
- First Posted Date
- 2020-05-15
- Last Posted Date
- 2022-02-25
- Lead Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Target Recruit Count
- 138
- Registration Number
- NCT04389073
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Beijing Huanxing Cancer Hospital, Beijing, Beijing, China
Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer
- Conditions
- Stage IIIA Bladder Cancer AJCC v8Muscle Invasive Bladder CarcinomaStage II Bladder Cancer AJCC v8
- Interventions
- Drug: CisplatinDrug: DoxorubicinDrug: MethotrexateBiological: PegfilgrastimBiological: PembrolizumabProcedure: Radical CystectomyDrug: Vinblastine Sulfate
- First Posted Date
- 2020-05-12
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 17
- Registration Number
- NCT04383743
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
- Conditions
- Lung NeoplasmsCarcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2020-05-08
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 870
- Registration Number
- NCT04380636
- Locations
- 🇺🇸
Torrance Memorial Physician Network / Cancer Center ( Site 0093), Torrance, California, United States
🇺🇸UCLA Hematology/Oncology - Santa Monica ( Site 0013), Los Angeles, California, United States
🇺🇸Miami VA Healthcare System ( Site 0024), Miami, Florida, United States
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
- Conditions
- Gastric Cancer
- Interventions
- Drug: Fluorouracil (5-FU)Biological: DurvalumabDrug: CapecitabineDrug: Trastuzumab deruxtecanDrug: OxaliplatinBiological: PembrolizumabBiological: TrastuzumabBiological: VolrustomigBiological: RilvegostomigDrug: Cisplatin
- First Posted Date
- 2020-05-07
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 413
- Registration Number
- NCT04379596
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy
- Conditions
- Stage IIIA Lung Cancer AJCC v8Stage IIIB Lung Cancer AJCC v8Locally Advanced Lung Non-Small Cell CarcinomaStage III Lung Cancer AJCC v8Stage IIIC Lung Cancer AJCC v8
- Interventions
- Drug: CisplatinBiological: DurvalumabDrug: EtoposideRadiation: Hypofractionated Radiation TherapyDrug: Pemetrexed
- First Posted Date
- 2020-05-04
- Last Posted Date
- 2023-06-13
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 1
- Registration Number
- NCT04372927
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for "Intermediate Risk" HPV-16-associated Head and Neck Squamous Cell Carcinoma
- Conditions
- HPV-Related Squamous Cell CarcinomaHead and Neck Squamous Cell Carcinoma
- Interventions
- Radiation: IMRT (Intensity Modulated Radiotherapy)Drug: PembrolizumabDrug: CisplatinBiological: ISA101b
- First Posted Date
- 2020-04-30
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Dan Zandberg
- Target Recruit Count
- 18
- Registration Number
- NCT04369937
- Locations
- 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA)
- Conditions
- Lung CancerNSCLC
- Interventions
- First Posted Date
- 2020-04-29
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Nasser Hanna
- Target Recruit Count
- 100
- Registration Number
- NCT04367311
- Locations
- 🇺🇸
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸University of Virginia Health System, Charlottesville, Virginia, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
Rituximab Plus Chemotherapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- Conditions
- Head and Neck Squamous Carcinoma
- Interventions
- First Posted Date
- 2020-04-24
- Last Posted Date
- 2020-04-28
- Lead Sponsor
- China Medical University Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT04361409
- Locations
- 🇨🇳
China medical University hospital, Taichung, Taiwan
Trial Evaluating Adapted Chemotherapy in Patients With Squamous Carcinoma
- Conditions
- Cancer of Head and Neck
- Interventions
- First Posted Date
- 2020-04-22
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Groupe Oncologie Radiotherapie Tete et Cou
- Target Recruit Count
- 105
- Registration Number
- NCT04356170
- Locations
- 🇫🇷
Centre Leon Berard, Lyon, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.